Axovant Sciences (NASDAQ:AXON) was downgraded by research analysts at Cowen from an “outperform” rating to a “market perform” rating in a research note issued to investors on Friday, January 12th.
A number of other research firms have also recently weighed in on AXON. Chardan Capital upgraded shares of Axovant Sciences from a “sell” rating to a “neutral” rating and set a $2.50 price objective on the stock in a research report on Wednesday, January 10th. ValuEngine downgraded Axovant Sciences from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Jefferies Group downgraded Axovant Sciences from a “buy” rating to a “hold” rating and set a $6.00 price target on the stock. in a research note on Thursday, December 21st. BidaskClub downgraded Axovant Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, December 2nd. Finally, HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Axovant Sciences in a research report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company’s stock. Axovant Sciences currently has a consensus rating of “Hold” and an average target price of $13.61.
Axovant Sciences (NASDAQ:AXON) traded down $0.01 during mid-day trading on Friday, hitting $1.97. 377,751 shares of the stock traded hands, compared to its average volume of 2,289,152. The stock has a market capitalization of $206.80, a P/E ratio of -0.85 and a beta of -0.97. The company has a debt-to-equity ratio of 0.34, a current ratio of 5.94 and a quick ratio of 5.94. Axovant Sciences has a 1 year low of $1.88 and a 1 year high of $27.98.
A number of large investors have recently modified their holdings of the stock. Legal & General Group Plc grew its stake in shares of Axovant Sciences by 20.2% during the 2nd quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock worth $162,000 after purchasing an additional 1,168 shares during the period. Russell Investments Group Ltd. lifted its holdings in Axovant Sciences by 38.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock valued at $233,000 after purchasing an additional 2,789 shares in the last quarter. Voya Investment Management LLC purchased a new position in Axovant Sciences in the 2nd quarter valued at $323,000. Laurion Capital Management LP purchased a new position in Axovant Sciences in the 2nd quarter valued at $336,000. Finally, Oppenheimer & Co. Inc. purchased a new position in Axovant Sciences in the 3rd quarter valued at $101,000. Institutional investors and hedge funds own 96.96% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/06/axovant-sciences-axon-downgraded-to-market-perform-at-cowen.html.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.